Sébastien Cimarelli, Dorra Ben Sellem, Alessio Imperiale, Alina Onea, Steve Heymann, Cyrille Blondet, Marcelo Clariá, Christian Goetz, André Constantinesco, Service de Biophysique et Médecine Nucléaire, CHU Strasbourg-Université Louis Pasteur - Strasbourg I-Hôpital de Hautepierre [Strasbourg], Centre Paul Strauss, CRLCC Paul Strauss, Institut de Mécanique des Fluides et des Solides (IMFS), École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Centre National de la Recherche Scientifique (CNRS), and Zimmer, Audrey
Prognosis of patients with Bartholin’s gland carcinoma(BGC) is strictly related to the nodal stage at diagnosis. Thus, it iscrucial to perform reliable staging for optimal treatment planning. Inspite of wide clinical utilization of F-18 FDG PET in oncologicalroutine, its role in vulvar malignancies is not completely defined. Tokeep organs and preserve anal and ureteral function, a patient withadvanced undifferentiated BGC (FIGO IV-A) received 50 Gy to thewhole pelvis, whole vagina and bilateral inguinal lymph nodes withconcomitant chemotherapy, followed by interstitial brachytherapy.F-18 FDG PET-CT was performed at staging and after treatmentcompletion. Complete regression of the initial metabolic abnormal-ities was shown on posttreatment images, confirming the efficacy ofthe adopted conservative approach. F-18 FDG PET-CT imagingcould have a role in staging and assessing treatment efficacy inaggressive BGC. Key Words: Bartholin’s gland carcinoma, undifferentiatedcarcinoma, F-18 FDG PET, chemoradiation, brachytherapy(